Outsourcing Glycan Analysis

Pharmaceutical Technology Europe spoke with Aled Jones, senior I product and applications manager at ProZyme; Philip Widdowson, European Application Development Scientist at Thermo Fisher Scientific; and Daryl Fernandes, chief executive at Ludger Ltd about the challenges of performing glycan analysi...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical technology Europe 2018-08, Vol.30 (8), p.16-17
Main Author: Haigney, Susan
Format: Article
Language:English
Subjects:
Chromatography
Corporate sponsorship
Mass spectrometry
Methods
Outsourcing
Quality
Scientific imaging
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmaceutical Technology Europe spoke with Aled Jones, senior I product and applications manager at ProZyme; Philip Widdowson, European Application Development Scientist at Thermo Fisher Scientific; and Daryl Fernandes, chief executive at Ludger Ltd about the challenges of performing glycan analysis and how outsourcing companies can offer specific expertise. Glycans are commonly released from the protein prior to analysis; however, the chemical properties of glycans make them difficult to analyze in their native form. [...]glycans are required to be derivatized in order to make them amendable for traditional analytical methodologies (2). [...]glycan analysis for selection of clones to match your quality target product profile (QTPP) or in QbD [quality-by-design] studies to determine design space (DS) will typically require a very different performance profile from those needed for batch release. Jones (ProZyme): Smaller or earlystage companies may not have the personnel to perform glycan analysis, or the instrumentation required such as liquid chromatography with fluorescence detection, capillary electrophoresis, and mass spectrometry.
ISSN:1753-7967